Intraprostatic botulinum toxin type "A" injection in patients with benign prostatic hyperplasia and unsatisfactory response to medical therapy: A randomized, double-blind, controlled trial using urodynamic evaluation
Neurourology and Urodynamics Aug 30, 2017
Totaro A, et al. – Researchers tried to find out the effectiveness of botulinum neurotoxin A (BTA) in treating patients with benign prostatic hyperplasia (BPH) unresponsive to combined medical therapy (CMT), applying urodynamic investigations. These outcomes highlighted that intraprostatic BTA is safe and can improve lower urinary tract symptoms and QoL in patients with BPH and unsatisfactory response to combined medical therapy.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
